|

JAB-2485 (Aurora A inhibitor) Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1/2: 1

Top Sponsors

  • Jacobio Pharmaceuticals Co., Ltd.1

Indications

  • ER+ Breast Cancer1
  • ARID1A Gene Mutation1
  • Small Cell Lung Cancer (SCLC)1
  • Solid Tumors1
  • Triple Negative Breast Cancer (TNBC)1

Detroit, Michigan1 trial

JAB-2485 Activity in Adult Patients With Advanced Solid Tumors

Henry Ford Health System

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.